1. Home
  2. SYNX vs IMRN Comparison

SYNX vs IMRN Comparison

Compare SYNX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$0.98

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.83

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYNX
IMRN
Founded
2005
1994
Country
Israel
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
6.2M
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
SYNX
IMRN
Price
$0.98
$0.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.2M
19.6K
Earning Date
05-01-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$32.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.68
52 Week High
$2.15
$2.38

Technical Indicators

Market Signals
Indicator
SYNX
IMRN
Relative Strength Index (RSI) 43.40 53.34
Support Level $0.93 $0.69
Resistance Level $1.31 $0.89
Average True Range (ATR) 0.09 0.06
MACD -0.02 0.01
Stochastic Oscillator 21.27 57.07

Price Performance

Historical Comparison
SYNX
IMRN

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: